|Year : 2019 | Volume
| Issue : 1 | Page : 51-57
Assessment of quality of life before and after successful percutaneous transvenous mitral commissurotomy in patients with severe mitral stenosis
Prashant Bhardwaj1, Suprakash Chaudhury2, Aradhana Aneja3, Vinay Jetley1, Tejvir Singh Walia3, Swaleha Mujawar2
1 Department of Cardiology, MH (CTC) and AFMC, Pune, Maharashtra, India
2 Department of Psychiatry, Dr. D. Y. Patil Medical College, Hospital and Research Centre, Dr. D. Y. Patil Vidyapeeth, Pune, Maharashtra, India
3 Department of Psychiatry, AFMC, Pune, Maharashtra, India
|Date of Submission||04-Jan-2019|
|Date of Acceptance||11-Jul-2019|
|Date of Web Publication||11-Dec-2019|
Dr. Tejvir Singh Walia
Department of Psychiatry, AFMC, Pune - 411 018, Maharashtra
Source of Support: None, Conflict of Interest: None
| Abstract|| |
Background: Rheumatic mitral stenosis (MS) is a significant cause of morbidity and mortality in India. Percutaneous transvenous mitral commissurotomy (PTMC) has become the procedure of choice for severe MS with pliable leaflets. Despite a wealth of literature on the technical aspects of PTMC, there is a dearth of literature addressing the impact of PTMC on the quality of life (QOL). Aim: The aim of the study is to assess the impact of PTMC on clinical status and QOL of patients with severe MS. Materials and Methods: Twenty-five consecutive patients with severe MS undergoing PTMC were included in the study with their informed consent. All patients were subjected to routine blood tests, electrocardiogram, chest X-ray, two-dimensional and color echocardiography, treadmill test (TMT), and World Health Organization (WHO) QOL scale. The echocardiography, TMT, and WHOQOL scale were repeated after the procedure. Results: The procedural success was 98%. The mean (range) mitral valve area preprocedure was 0.82 (0.59–0.92) cm2 and postprocedure was 1.61 (1.51–1.76) cm2. The difference was statistically significant (t = 5.02; P < 0.01). The mean (range) of TMT preprocedure was 4.05 (3.0–7.0) METS and postprocedure was 8.52 (6–12) METS. The difference was statistically significant (T = 3.08; P < 0.01). The mean (range) of QOL assessment pre- and post-procedure on physical domain was 8.83 (8.3–10.1) which increased to 11.11 (10–12.7); on social relationship domain from 9.17 (7.5–12.4) to 11.37 (9.4–12.0); on personal relationship from 11.6 (11–13) to 12.52 (12–13); on environment domain from 10.78 (10.2–11.7) to 11.56 (10.8–12); and on level of independence from 9.02 (8–10) to 12.29 (11.0–13.6). All the differences were statistically significant (Wilcoxon signed-rank test z = −4.376; −4.379; −4.234; −4.200; −4.375; respectively, all P < 0.001 highly significant). Conclusions: PTMC resulted in a significant improvement in the QOL of patients with severe MS. The significant improvement in QOL post-PTMC may be an indication for offering PTMC at an earlier stage to those patients whose QOL is severely compromised.
Keywords: Mitral stenosis, percutaneous transvenous mitral commissurotomy, quality of life
|How to cite this article:|
Bhardwaj P, Chaudhury S, Aneja A, Jetley V, Walia TS, Mujawar S. Assessment of quality of life before and after successful percutaneous transvenous mitral commissurotomy in patients with severe mitral stenosis. Ind Psychiatry J 2019;28:51-7
|How to cite this URL:|
Bhardwaj P, Chaudhury S, Aneja A, Jetley V, Walia TS, Mujawar S. Assessment of quality of life before and after successful percutaneous transvenous mitral commissurotomy in patients with severe mitral stenosis. Ind Psychiatry J [serial online] 2019 [cited 2020 Aug 3];28:51-7. Available from: http://www.industrialpsychiatry.org/text.asp?2019/28/1/51/272689
According to the World Health Organization (WHO), quality of life (QOL) is defined as “the individual's perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals.” “The degree of need and satisfaction within the physical, psychological, social, activity, material, and structural area;” “…the individuals' perception of their position in life in the context of the culture and value systems in which they live, and in relation to their goals, expectations, standards and concerns;” and “…a state of well-being which is a composite of two components: the ability to perform everyday activities which reflects physical, psychological, and social well-being and patient satisfaction with levels of functioning and the control of disease- and/or treatment-related symptoms.” QOL is the general well-being of individuals and societies. It encompasses life satisfaction, physical health, family, education, employment, wealth, religious beliefs, finance, and the environment. It gives an idea about how the individual's well-being may be influenced over time by a disease, disability, or disorder. The current concept of QOL in health care needs the individuals to put their actual situation in relation to their personal expectation. The understanding of QOL is an important health-care topic because the relationship between cost and value raises complex problems, often with high emotional attachment because of the potential impact on human life. It can be used as a key performance metric when designing and implementing organizational change initiatives.
Rheumatic mitral stenosis (MS) continues to be a significant cause of morbidity and mortality in our country. It is a major burden in developing countries where it causes most of the cardiovascular morbidity and mortality in young people, leading to about 250,000 deaths/year worldwide. The lesion if left untreated imposes a significant burden on the individual and the society in terms of both health and finances. MS is the prototype of rheumatic heart disease. In the West, it usually takes decades from the onset of rheumatic valvulitis until significant symptomatic obstruction occurs. This period is considerably shortened in the tropical countries. In developing countries, the latent period has been reported to be as short as 3 years., The symptoms of MS are mainly due to the effect of the stenosis on the left atrial pressure and size. Increased left atrial pressures lead to elevation of pulmonary venous pressure, and this causes exertional dyspnea in patients. Further, progression of disease and elevation of pressure lead to paroxysmal nocturnal dyspnea and orthopnea. The increase in the left atrial size causes pressure symptoms at times in the form of hoarseness of voice; more commonly, it causes atrial fibrillation and consequence thereof. The disease once symptomatic has a steady progressive curve, which can be controlled in the initial stages by drugs. The relentless progression of the disease, however, soon renders drug therapy ineffective and one has to intervene to mechanically increase the valve area, thereby abrogating the elevated left atrial pressure.
Surgical mitral commissurotomy was the treatment of choice for severe MS till 1984 when Inou et al. first described percutaneous transvenous mitral commissurotomy (PTMC). Since then, PTMC has shown excellent results., The options available for the treatment of severe MS at present are closed mitral valvutomy, open mitral valvutomy, and percutaneous mitral commissurotomy (PTMC). The first procedure entails a thoracotomy, the second an open heart surgery, whereas the third can be done under local anesthesia. The operation mortality of surgery is 4.7% and that of PTMC is <1%. PTMC is a procedure that involves passing a balloon catheter from the right atrium through the intra-arterial septum into the left atrium and then across the stenotic mitral valve into the left ventricle. This procedure which is performed under local anesthesia produces immediate hemodynamic improvement and relieves congestive symptoms. It has become the procedure of choice for MS in symptomatic patients with optimum valve morphology. The patient has to be is symptomatic prior to being considered for PTMC on ordinary physical activity (Class II New York Heart Association [NYHA]).
The disease symptoms can be a nightmare literally and figuratively and the apprehension increases as time passes by. The recurrence of symptoms imposes a significant impact on the QOL of the individual and the family. Although rheumatic MS is more common in females, it usually impacts the whole family, especially if the lady of the house is affected. There is plenty of literature on the technical aspects of PTMC in terms of hemodynamics, valve areas, and objective symptomatic relief, but there is a paucity of studies addressing the impact of PTMC on QOL. In view of the lack of studies in this area, the present work was undertaken to assess the impact of PTMC on the QOL of patients with MS.
| Materials And Methods|| |
This prospective, longitudinal, hospital-based study was undertaken in the Department of Cardiology, Military Hospital (Cardiothoracic Centre) and Armed Forces Medical College, Pune. The project was approved by the institutional ethical committee and all the participants gave written informed consent.
The sample for the study consisted of consecutive patients with severe MS with a mitral valve surface area of equal to or <1 cm2 and pliable valves meeting the following exclusion criteria were included in the study with their consent.
Exclusion criteria for percutaneous transvenous mitral commissurotomy were
- Grade III or Grade IV mitral regurgitation
- Wilkin score of >8
- Presence of a left atrial thrombosis
- Significant aortic valve disease
- Not giving consent for taking part in the study.
World Health Organization quality of life
The WHOQOL was developed collaboratively in 15 culturally diverse field centers around the world. It is used to measure the perception of an individual of their position in life in the context of the culture and value systems in which they live. It has been rigorously tested to assess its validity and reliability. The WHOQOL produces a multidimensional profile of scores across six domains – Physical, Psychological, Level of Independence, Social Relationships, Environment, Spirituality, and 24 subdomains of QOL.,
Functional status of the patients was assessed by the NYHA criteria. All patients were subjected to routine blood tests, which included blood hemoglobin, total leukocyte count, differential leukocyte count, bleeding time, clotting time, serum glucose, blood urea, serum creatinine, and liver function tests. A 12-lead electrocardiogram, chest X-ray posteroanterior view, and echocardiography (two-dimensional and color) were done. Patients were also subjected to an objective assessment of their physical performance on the treadmill using the Bruce protocol. The echocardiography and treadmill test (TMT) were repeated after PTMC. PTMC was performed using an anterograde approach from the femoral vein. The transseptal puncture was done by the Brockenborough needle, and the Inoue balloon was positioned across the mitral valve. The balloon inflation was done in this position valvotomy was done. Successful PTMC was defined as a postprocedural mitral valve area (MVA) of 1.5 cm2 or more or percentage increase in MVA of ≥50% in the absence of major complications, including death, systemic embolism, and cardiac tamponade. Procedural mortality was defined as death within 24 h of PTMC.
All patients also underwent an evaluation of QOL using the WHOQOL questionnaire 1 day before and after the procedure.
The collected data were analyzed using the Statistical Package for the Social Sciences version 16.0 (IBM, USA). For comparison of data, appropriate statistical tests (Independent sample t-test, Wilcoxon signed rank test, and Pearson's correlation) were used. Statistical analyses were performed with a significance level of <0.05 and a confidence level of 95%.
| Results|| |
The total number of patients who underwent PTMC during the study period was 25, which included 8 male and 17 female patients. The mean (± standard deviation) age of the patients was 26.2 (+ 11.2) years. The NYHA status of the patients was as follows: Class II – 3 (12.0%), Class III – 19.0 (76.0%), and Class IV – 3 (12.0%). The procedural success was 98%. The MVA preprocedure ranged from 0.59 to 0.92 cm2 and postprocedure was 1.51–1.76 cm2. The treadmill performed preprocedure ranged from 3.0 to 7.0 METS and postprocedure was 6–12 METS. The procedural results in terms of MVA and performance on treadmill before and after PTMC are given in [Table 1] and [Figure 1]. [Table 2] shows changes in mean MVA pre- and post-procedure of the present study along with few earlier studies.
|Table 1: Mitral valve area and performance on treadmill before and after percutaneous transvenous mitral commissurotomy|
Click here to view
|Figure 1: Mitral valve area and treadmill test results before and after percutaneous transvenous mitral commissurotomy|
Click here to view
|Table 2: Mean mitral valve area pre- and post-percutaneous transvenous mitral commissurotomy procedure of the present study and few earlier studies|
Click here to view
The QOL assessment on the physical domain preprocedure was 8.3–10.1, which increased to 10–12.7 postprocedure. The social relationship domain score increased from 7.5–12.4 preprocedure to 9.4–12.0 postPTMC. The personal relationship score was 11–13 and 12–13 pre- and post-PTMC, respectively. The environment domain was 10.2–11.7 preprocedure to 10.8–12 postprocedure. The level of independence ranged from 8–10 pre-PTMC to 11.0–13.6 post-PTMC. The results of WHOQOL assessment domain scores before and after PTMC are given in [Table 3]. Correlations of WHOQOL domain scores with MVA and TMT scores after PTMC are given in [Table 4] and [Table 5], respectively.
|Table 3: Results of the World Health Organization quality of life domain scores of the patients before and after percutaneous transvenous mitral commissurotomy|
Click here to view
|Table 4: Correlations of mitral valve area with World Health Organization quality of life domain scores after percutaneous transvenous mitral commissurotomy|
Click here to view
|Table 5: Correlations of treadmill test results with World Health Organization Quality Of Life domain scores after percutaneous transvenous mitral commissurotomy|
Click here to view
| Discussion|| |
It is obvious from the literature that in developing countries like India, MS predominantly affects a younger population and the majority of symptomatic MS patients usually present before the age of 30 years and our findings are in agreement with these studies.,,,,,,,, On the other hand, in Western countries, the disease primarily involves the older population as shown in a series of PTMC reported from developed countries. In addition, reports indicate that the progression of symptoms of rheumatic MS in this part of the world is very rapid. In an earlier study, >85% of the patients were in functional Class III/IV at the time of presentation. The age distribution and female preponderance of our patients were similar to other studies from developing countries.,
PTMC using the Inoue technique was first reported by Inoue et al. in 1984. Since then, it has evolved and rapidly became the standard technique for the management of MS with pliable valves. The results of PTMC in adults are similar to that of open commissurotomy and better than that of closed commissurotomy., Studies have found that PTMC with use of simple height-based balloon sizing method in the step-wise Inoue balloon approach is associated with excellent short-term and long-term efficacy rates and a low risk of creating severe mitral regurgitation.
The present study reported statistically significant difference between pre- and post-procedure MVA (cm2) after PTMC (0.83 ± 0.08 vs. 1.61 ± 0.07). According to Munir et al., Adhikari et al., Ali et al., and Sharma et al., PTMC significantly directly increases the rate of perioperative MVA (cm2) as 0.92 ± 0.39 vs. 1.48 ± 0.29, 0.8 ± 0.1 vs. 1.6 ± 0.2, 0.684 ± 0.1226 vs. 1.533 ± 0.281, and 0.87 ± 0.13 vs. 1.63 ± 0.19, respectively. The results of the present study are similar to the above results. In accordance with the above, the patients in the study cohort had a demonstrable increase in their performance on the treadmill after PTMC. This was not uniformly correlated to the valve area but was related to pre-PTMC physical statistics and the well-known variable hemodynamic effects of flow and valve area.
Many patients of MS present with respiratory symptoms. The chronic changes in the pulmonary circulation are secondary to increased pulmonary venous pressure and reflex pulmonary artery vasoconstriction. Accumulation of water, proteins, and proteoglycans in the interstitium of the lungs are the basis of the clinical manifestations of MS and can be detected by pulmonary function tests also the residual volume function may be altered due to an increase in the left atrial pressure. Few recent studies have shown that successful PTMC immediately improves cardiac and pulmonary function along with the clinical status of patients with MS.,
Despite the availability of standardized scales for assessment of QOL the literature on the assessment of QOL in patients with rheumatic MS is rare, and no study has assessed the effects of PTMC on QOL. Chronic rheumatic disease is associated with increased physical and psychosocial impairments including pain, fatigue, and difficulties with activities of daily living, ranging from basic household chores to more complex tasks such as employment and social roles, e.g., childbearing. Moreover, chronic rheumatic disease requires long-term prophylactic treatment, including painful administration of intramuscular medication. Due to these reasons, it causes stress and anxiety in patients resulting in impaired QOL. In addition, rheumatic MS may cause functional and psychosocial limitations that contribute to further deteriorate the patient's QOL.,,
The impact of PTMC on the QOL of patients with severe MS in this study was remarkable as seen by significant correlation of MVA and TMT scores postprocedure with WHOQOL domain scores [Table 4] and [Table 5] and the significant improvement of all WHOQOL domain scores after the procedure compared to the preprocedure scores [Table 3]. The maximum impact was seen only in the physical and level of independence domain and less on social personal and environment domains. The reason for this is probably because the relief of physical symptoms occurs immediately after PTMC, while the social changes are likely to occur after discharge from the hospital. Since the post-PTMC assessment was done prior to discharge from the hospital only, the changes in physical and level of independence domain of QOL were evident. However, even this improvement in the physical and level of independence domain has an important effect in improving the QOL, personal confidence, and ability of the patients. Being a pioneering study measuring the QOL of patients before and after PTMS, comparison of the findings of the present study with other studies is not possible.
The present study has certain limitations. The sample size was rather small and no follow-up could be done due to the limitation of time for our study. Hence, future studies with larger sample and longer follow-up are suggested.
| Conclusions and Recommendations|| |
PTMC has a very significant impact on the QOL of patients most so in the physical and level of independence domains. This quality enhances the confidence, self-esteem, and mood of the patient. Hence, for a better QOL, this procedure should be advised in patients with MS. It is recommended that the assessment of QOL should be carried out routinely in all cases of severe MS. The significant improvement in QOL post-PTMC may be an indication for offering PTMC at an earlier stage to those patients whose QOL is severely compromised.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
McNally J W. Encyclopedia of the Life Course and Human Development. 1st
ed., Vol. 3. USA: Macmillan Reference; 2009. p. 317.
Kowitt SD, Nan H, Speight J. Quality of life and person-centered outcomes: Considerations for behavioral medicine. In: Fisher EB, editor. Principles and Concepts of Behavioral Medicine. New York: Springer; 2018. p. 987-1020.
Jongen PJ, Lehnick D, Sanders E, Seeldrayers P, Fredrikson S, Andersson M, et al.
Health-related quality of life in relapsing remitting multiple sclerosis patients during treatment with glatiramer acetate: A prospective, observational, international, multi-centre study. Health Qual Life Outcomes 2010;8:133.
Mitchell JM, Kemp BJ. Quality of life in assisted living homes: A multidimensional analysis. J Gerontol B Psychol Sci Soc Sci 2000;55:P117-27.
Chandrashekhar Y, Westaby S, Narula J. Mitral stenosis. Lancet 2009;374:1271-83.
Marijon E, Mirabel M, Celermajer DS, Jouven X. Rheumatic heart disease. Lancet 2012;379:953-64.
Yonga GO, Bonhoeffer P. Percutaneous transvenous mitral commissurotomy in juvenile mitral stenosis. East Afr Med J 2003;80:172-4.
Shrestha M, Adhikari CM, Shakya U, Khanal A, Shreshtra S, Rajbhandari R. Percutaneous transluminal mitral commissurotomy in Nepalese children with rheumatic mitral stenosis. Nepal Heart J 2013;10:23-6.
Inoue K, Owaki T, Nakamura T, Kitamura F, Miyamoto N. Clinical application of transvenous mitral commissurotomy by a new balloon catheter. J Thorac Cardiovasc Surg 1984;87:394-402.
Rahman T. Immediate outcome of percutaneous transvenous mitral commissurotomy in elderly severe mitral stenosis patients. J Am Coll Cardiol 2016;67 Suppl 13:351.
Babar HA, Saad AA, Butt ZR, Khan Z, Dastgeer S, Iqbal MM. Severe mitral stenosis: In-hospital outcomes of percutaneous transvenous mitral commissurotomy (PTMC) in patients. Prof Med J 2017;24:850-4.
Nobuyoshi M, Arita T, Shirai S, Hamasaki N, Yokoi H, Iwabuchi M, et al.
Percutaneous balloon mitral valvuloplasty: A review. Circulation 2009;119:e211-9.
The World Health Organization quality of life assessment (WHOQOL): Position paper from the World Health Organization. Soc Sci Med 1995;41:1403-9.
Development of the World Health Organization WHOQOL-BREF quality of life assessment. The WHOQOL group. Psychol Med 1998;28:551-8.
Arora R, Kalra GS, Singh S, Mukhopadhyay S, Kumar A, Mohan JC, et al.
Percutaneous transvenous mitral commissurotomy: Immediate and long-term follow-up results. Catheter Cardiovasc Interv 2002;55:450-6.
Kothari SS, Ramakrishnan S, Juneja R, Yadav R. Percutaneous transvenous mitral commissurotomy in patients with severe mitral stenosis and acute rheumatic fever. Pediatr Cardiol 2006;27:347-50.
Wilson V, Gupta N, Prabhakar P, Ramakrishnan L, Seth S, Maulik SK, et al
. Effect of percutaneous transvenous mitral commissurotomy on plasma apelin level in mitral stenosis patients. J Clin Exp Cardiol 2014;5:283.
Adhikari CM, Malla R, Rajbhandari R, Shakya U, Sharma P, Shrestha N, et al.
Percutaneous transvenous mitral commissurotomy in juvenile mitral stenosis. Cardiovasc Diagn Ther 2016;6:20-4.
Ali L, Asghar N, Riaz R, Hussain M. Percutaneous transmitral commissurotomy (PTMC); Procedural success and immediate results, a tertiary care hospital experience from developing country. Prof Med J 2016;23:104-13.
Khan I, Shah B, Habeel Dar M, Khan A, Faisal Iftekhar M, Sami A. Clinical and echocardiographic follow-up after successful percutaneous transvenous mitral commissurotomy. Cureus 2017;9:e1726.
Munir S, Akbara MA, Alamgirb A, Alia SA, Iqbala M. Immediate results of percutaneous transmitral commissurotomy (PTMC) in a tertiary care hospital Punjab institute of cardiology, Lahore, Pakistan. J Cardiovasc Dis 2018;14:22-5.
Misra M, Mittal M, Singh R, Verma A, Rai R, Chandra G, et al.
Prevalence of rheumatic heart disease in school-going children of Eastern Uttar Pradesh. Indian Heart J 2007;59:42-3.
Farman MT, Khan N, Sial JA, Saghir T, Ashraf T, Rasool SI, et al.
Predictors of successful percutaneous transvenous mitral commissurotomy using the Bonhoeffer multi-track system in patients with moderate to severe mitral stenosis: Can we see beyond the Wilkins score? Anatol J Cardiol 2015;15:373-9.
Hernandez R, Bañuelos C, Alfonso F, Goicolea J, Fernández-Ortiz A, Escaned J, et al.
Long-term clinical and echocardiographic follow-up after percutaneous mitral valvuloplasty with the Inoue balloon. Circulation 1999;99:1580-6.
Murthy Jayanthi Sriram SN, Venkata BJ, Sadagopan T, Ramamurthy MT. Immediate, intermediate and long term clinical outcomes of percutaneous transvenous mitral commissurotomy. Int J Cardiol Heart Vasc 2015;6:66-70.
Rajbhandari R, Malla R, Maskey A, Bhatta Y, Limbu Y, Sharma R, et al.
Percutaneous transvenous mitral commissurotomy in mitral stenosis and left atrial appendage clot patients in special conditions: Hospital-based study. Indian Heart J 2016;68:788-91.
Ben Farhat M, Ayari M, Maatouk F, Betbout F, Gamra H, Jarra M, et al
. Pecutaneous balloon versus surgical closed and open mitral commissurotomy: Seven year follow-up results of a randomised trial. Circulation 1998;97:245-50.
Reyes VP, Raju BS, Wynne J, Stephenson LW, Raju R, Fromm BS, et al.
Percutaneous balloon valvuloplasty compared with open surgical commissurotomy for mitral stenosis. N
Engl J Med 1994;331:961-7.
Sharma KH, Jain S, Shukla A, Bohora S, Roy B, Gandhi GD, et al.
Patient profile and results of percutaneous transvenous mitral commissurotomy in mitral restenosis following prior percutaneous transvenous mitral commissurotomy vs. surgical commissurotomy. Indian Heart J 2014;66:164-8.
Santosh Kumar C, Rajasekhar D, Vanajakshamma V, Boochi Babu M. The immediate and short term impact of successful percutaneous transvenous mitral commissurotomy on right ventricular function. Cardiovasc Dis Diagn 2015;3:5.
Khan US, Islam AK Majumder AL. Effect of successful percutaneous transvenous mitral commissurotomy on pulmonary function. Bangladesh Heart J 2017;32:45-9.
Nunes MC, Nascimento BR, Lodi-Junqueira L, Tan TC, Athayde GR, Hung J. Update on percutaneous mitral commissurotomy. Heart 2016;102:500-7.
Carvalho MF, Bloch KV, Oliveira SK. Quality of life of children and adolescents with rheumatic fever. J Pediatr (Rio J) 2009;85:438-42.
Riaz A, Hanif MI, Khan IH, Hanif A, Mughal S, Anwer A. Quality of life in patients with rheumatic heart disease. J Pak Med Assoc 2018;68:370-5.
[Table 1], [Table 2], [Table 3], [Table 4], [Table 5]